世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
融合阻害剤 - 世界市場シェアとランキング、全体売上高と需要予測 2024-2030Fusion Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 融合阻害剤の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％CAGRで2030年までに100万米ドルの再調整された規模になると予測されています。 融合阻害剤の北米市場は... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー融合阻害剤の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％CAGRで2030年までに100万米ドルの再調整された規模になると予測されています。融合阻害剤の北米市場は、2023年に百万米ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに百万米ドルに達すると予測されています。 融合阻害剤のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 融合阻害剤のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するでしょう。 融合阻害剤の世界の主要企業には、Bristol-Myers Squibb Company、PeptidePharma、Incyte、Astrazeneca、ViiV Healthcare Limited、Frontier Bio Corporation、Trimeris, Inc、Progenics Pharmaceuticals、Schering-Plough (Merck & Co.)などがある。2023年には、世界の大手5社が売上高で約 %のシェアを占めている。 レポートの範囲 本レポートは、Fusion Inhibitorsの世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総販売量、販売収益、価格、主要企業の市場シェア、ランキングに焦点を当て、包括的なプレゼンテーションを提供することを目的としています。 融合阻害剤の市場規模、推計、予測は、2023年を基準年とし、2019年から2030年までの期間の履歴データと予測データを加えた販売数量（Kユニット）と販売収益（百万ドル）で提供されます。定量的、定性的分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、Fusion Inhibitorsに関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 ブリストル・マイヤーズ スクイブ社 ペプチドファーマ インサイト アストラゼネカ ヴィーブヘルスケア フロンティアバイオ株式会社 トリメリス社 プロジェニクス・ファーマシューティカルズ シェリング・プラウ（メルク・アンド・カンパニー） バイオジェン ヴァンダービルト大学 ジェネンテック タイプ別セグメント 非経口剤 経口 用途別セグメント 小売薬局 オンライン薬局 その他 地域別 北米 アメリカ カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章： レポートの対象範囲、世界の総市場規模（バルブ、数量、価格）を紹介。この章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章：融合阻害剤メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章：各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模と発展可能性を網羅し、読者が各市場セグメントのブルーオーシャン市場を見つけやすくします。 第4章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのに役立ちます。 第5章：地域レベルでの融合阻害剤の販売、収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、市場規模を紹介しています。 第6章 融合阻害剤の国別売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロファイルを提供し、製品の売上高、収益、価格、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Fusion Inhibitors Product Introduction 1.2 Global Fusion Inhibitors Market Size Forecast 1.2.1 Global Fusion Inhibitors Sales Value (2019-2030) 1.2.2 Global Fusion Inhibitors Sales Volume (2019-2030) 1.2.3 Global Fusion Inhibitors Sales Price (2019-2030) 1.3 Fusion Inhibitors Market Trends & Drivers 1.3.1 Fusion Inhibitors Industry Trends 1.3.2 Fusion Inhibitors Market Drivers & Opportunity 1.3.3 Fusion Inhibitors Market Challenges 1.3.4 Fusion Inhibitors Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Fusion Inhibitors Players Revenue Ranking (2023) 2.2 Global Fusion Inhibitors Revenue by Company (2019-2024) 2.3 Global Fusion Inhibitors Players Sales Volume Ranking (2023) 2.4 Global Fusion Inhibitors Sales Volume by Company Players (2019-2024) 2.5 Global Fusion Inhibitors Average Price by Company (2019-2024) 2.6 Key Manufacturers Fusion Inhibitors Manufacturing Base Distribution and Headquarters 2.7 Key Manufacturers Fusion Inhibitors Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Fusion Inhibitors 2.9 Fusion Inhibitors Market Competitive Analysis 2.9.1 Fusion Inhibitors Market Concentration Rate (2019-2024) 2.9.2 Global 5 and 10 Largest Manufacturers by Fusion Inhibitors Revenue in 2023 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fusion Inhibitors as of 2023) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Parenteral 3.1.2 Oral 3.2 Global Fusion Inhibitors Sales Value by Type 3.2.1 Global Fusion Inhibitors Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Fusion Inhibitors Sales Value, by Type (2019-2030) 3.2.3 Global Fusion Inhibitors Sales Value, by Type (%) (2019-2030) 3.3 Global Fusion Inhibitors Sales Volume by Type 3.3.1 Global Fusion Inhibitors Sales Volume by Type (2019 VS 2023 VS 2030) 3.3.2 Global Fusion Inhibitors Sales Volume, by Type (2019-2030) 3.3.3 Global Fusion Inhibitors Sales Volume, by Type (%) (2019-2030) 3.4 Global Fusion Inhibitors Average Price by Type (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Retail Pharmacies 4.1.2 Online Pharmacies 4.1.3 Others 4.2 Global Fusion Inhibitors Sales Value by Application 4.2.1 Global Fusion Inhibitors Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Fusion Inhibitors Sales Value, by Application (2019-2030) 4.2.3 Global Fusion Inhibitors Sales Value, by Application (%) (2019-2030) 4.3 Global Fusion Inhibitors Sales Volume by Application 4.3.1 Global Fusion Inhibitors Sales Volume by Application (2019 VS 2023 VS 2030) 4.3.2 Global Fusion Inhibitors Sales Volume, by Application (2019-2030) 4.3.3 Global Fusion Inhibitors Sales Volume, by Application (%) (2019-2030) 4.4 Global Fusion Inhibitors Average Price by Application (2019-2030) 5 Segmentation by Region 5.1 Global Fusion Inhibitors Sales Value by Region 5.1.1 Global Fusion Inhibitors Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Fusion Inhibitors Sales Value by Region (2019-2024) 5.1.3 Global Fusion Inhibitors Sales Value by Region (2025-2030) 5.1.4 Global Fusion Inhibitors Sales Value by Region (%), (2019-2030) 5.2 Global Fusion Inhibitors Sales Volume by Region 5.2.1 Global Fusion Inhibitors Sales Volume by Region: 2019 VS 2023 VS 2030 5.2.2 Global Fusion Inhibitors Sales Volume by Region (2019-2024) 5.2.3 Global Fusion Inhibitors Sales Volume by Region (2025-2030) 5.2.4 Global Fusion Inhibitors Sales Volume by Region (%), (2019-2030) 5.3 Global Fusion Inhibitors Average Price by Region (2019-2030) 5.4 North America 5.4.1 North America Fusion Inhibitors Sales Value, 2019-2030 5.4.2 North America Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 5.5 Europe 5.5.1 Europe Fusion Inhibitors Sales Value, 2019-2030 5.5.2 Europe Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 5.6 Asia Pacific 5.6.1 Asia Pacific Fusion Inhibitors Sales Value, 2019-2030 5.6.2 Asia Pacific Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 5.7 South America 5.7.1 South America Fusion Inhibitors Sales Value, 2019-2030 5.7.2 South America Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 5.8 Middle East & Africa 5.8.1 Middle East & Africa Fusion Inhibitors Sales Value, 2019-2030 5.8.2 Middle East & Africa Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Fusion Inhibitors Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Fusion Inhibitors Sales Value 6.2.1 Key Countries/Regions Fusion Inhibitors Sales Value, 2019-2030 6.2.2 Key Countries/Regions Fusion Inhibitors Sales Volume, 2019-2030 6.3 United States 6.3.1 United States Fusion Inhibitors Sales Value, 2019-2030 6.3.2 United States Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Fusion Inhibitors Sales Value, 2019-2030 6.4.2 Europe Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Fusion Inhibitors Sales Value, 2019-2030 6.5.2 China Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.5.3 China Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Fusion Inhibitors Sales Value, 2019-2030 6.6.2 Japan Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Fusion Inhibitors Sales Value, 2019-2030 6.7.2 South Korea Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Fusion Inhibitors Sales Value, 2019-2030 6.8.2 Southeast Asia Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Fusion Inhibitors Sales Value, 2019-2030 6.9.2 India Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.9.3 India Fusion Inhibitors Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Bristol-Myers Squibb Company 7.1.1 Bristol-Myers Squibb Company Company Information 7.1.2 Bristol-Myers Squibb Company Introduction and Business Overview 7.1.3 Bristol-Myers Squibb Company Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.1.4 Bristol-Myers Squibb Company Fusion Inhibitors Product Offerings 7.1.5 Bristol-Myers Squibb Company Recent Development 7.2 PeptidePharma 7.2.1 PeptidePharma Company Information 7.2.2 PeptidePharma Introduction and Business Overview 7.2.3 PeptidePharma Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.2.4 PeptidePharma Fusion Inhibitors Product Offerings 7.2.5 PeptidePharma Recent Development 7.3 Incyte 7.3.1 Incyte Company Information 7.3.2 Incyte Introduction and Business Overview 7.3.3 Incyte Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.3.4 Incyte Fusion Inhibitors Product Offerings 7.3.5 Incyte Recent Development 7.4 Astrazeneca 7.4.1 Astrazeneca Company Information 7.4.2 Astrazeneca Introduction and Business Overview 7.4.3 Astrazeneca Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.4.4 Astrazeneca Fusion Inhibitors Product Offerings 7.4.5 Astrazeneca Recent Development 7.5 ViiV Healthcare Limited 7.5.1 ViiV Healthcare Limited Company Information 7.5.2 ViiV Healthcare Limited Introduction and Business Overview 7.5.3 ViiV Healthcare Limited Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.5.4 ViiV Healthcare Limited Fusion Inhibitors Product Offerings 7.5.5 ViiV Healthcare Limited Recent Development 7.6 Frontier Bio Corporation 7.6.1 Frontier Bio Corporation Company Information 7.6.2 Frontier Bio Corporation Introduction and Business Overview 7.6.3 Frontier Bio Corporation Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.6.4 Frontier Bio Corporation Fusion Inhibitors Product Offerings 7.6.5 Frontier Bio Corporation Recent Development 7.7 Trimeris, Inc. 7.7.1 Trimeris, Inc. Company Information 7.7.2 Trimeris, Inc. Introduction and Business Overview 7.7.3 Trimeris, Inc. Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.7.4 Trimeris, Inc. Fusion Inhibitors Product Offerings 7.7.5 Trimeris, Inc. Recent Development 7.8 Progenics Pharmaceuticals 7.8.1 Progenics Pharmaceuticals Company Information 7.8.2 Progenics Pharmaceuticals Introduction and Business Overview 7.8.3 Progenics Pharmaceuticals Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.8.4 Progenics Pharmaceuticals Fusion Inhibitors Product Offerings 7.8.5 Progenics Pharmaceuticals Recent Development 7.9 Schering-Plough (Merck & Co.) 7.9.1 Schering-Plough (Merck & Co.) Company Information 7.9.2 Schering-Plough (Merck & Co.) Introduction and Business Overview 7.9.3 Schering-Plough (Merck & Co.) Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.9.4 Schering-Plough (Merck & Co.) Fusion Inhibitors Product Offerings 7.9.5 Schering-Plough (Merck & Co.) Recent Development 7.10 Biogen 7.10.1 Biogen Company Information 7.10.2 Biogen Introduction and Business Overview 7.10.3 Biogen Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.10.4 Biogen Fusion Inhibitors Product Offerings 7.10.5 Biogen Recent Development 7.11 Vanderbilt University 7.11.1 Vanderbilt University Company Information 7.11.2 Vanderbilt University Introduction and Business Overview 7.11.3 Vanderbilt University Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.11.4 Vanderbilt University Fusion Inhibitors Product Offerings 7.11.5 Vanderbilt University Recent Development 7.12 Genentech 7.12.1 Genentech Company Information 7.12.2 Genentech Introduction and Business Overview 7.12.3 Genentech Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.12.4 Genentech Fusion Inhibitors Product Offerings 7.12.5 Genentech Recent Development 8 Industry Chain Analysis 8.1 Fusion Inhibitors Industrial Chain 8.2 Fusion Inhibitors Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Fusion Inhibitors Sales Model 8.5.2 Sales Channel 8.5.3 Fusion Inhibitors Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Fusion Inhibitors was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 Fusion Inhibitors Product Introduction 1.2 Global Fusion Inhibitors Market Size Forecast 1.2.1 Global Fusion Inhibitors Sales Value (2019-2030) 1.2.2 Global Fusion Inhibitors Sales Volume (2019-2030) 1.2.3 Global Fusion Inhibitors Sales Price (2019-2030) 1.3 Fusion Inhibitors Market Trends & Drivers 1.3.1 Fusion Inhibitors Industry Trends 1.3.2 Fusion Inhibitors Market Drivers & Opportunity 1.3.3 Fusion Inhibitors Market Challenges 1.3.4 Fusion Inhibitors Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Fusion Inhibitors Players Revenue Ranking (2023) 2.2 Global Fusion Inhibitors Revenue by Company (2019-2024) 2.3 Global Fusion Inhibitors Players Sales Volume Ranking (2023) 2.4 Global Fusion Inhibitors Sales Volume by Company Players (2019-2024) 2.5 Global Fusion Inhibitors Average Price by Company (2019-2024) 2.6 Key Manufacturers Fusion Inhibitors Manufacturing Base Distribution and Headquarters 2.7 Key Manufacturers Fusion Inhibitors Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of Fusion Inhibitors 2.9 Fusion Inhibitors Market Competitive Analysis 2.9.1 Fusion Inhibitors Market Concentration Rate (2019-2024) 2.9.2 Global 5 and 10 Largest Manufacturers by Fusion Inhibitors Revenue in 2023 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fusion Inhibitors as of 2023) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Parenteral 3.1.2 Oral 3.2 Global Fusion Inhibitors Sales Value by Type 3.2.1 Global Fusion Inhibitors Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Fusion Inhibitors Sales Value, by Type (2019-2030) 3.2.3 Global Fusion Inhibitors Sales Value, by Type (%) (2019-2030) 3.3 Global Fusion Inhibitors Sales Volume by Type 3.3.1 Global Fusion Inhibitors Sales Volume by Type (2019 VS 2023 VS 2030) 3.3.2 Global Fusion Inhibitors Sales Volume, by Type (2019-2030) 3.3.3 Global Fusion Inhibitors Sales Volume, by Type (%) (2019-2030) 3.4 Global Fusion Inhibitors Average Price by Type (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Retail Pharmacies 4.1.2 Online Pharmacies 4.1.3 Others 4.2 Global Fusion Inhibitors Sales Value by Application 4.2.1 Global Fusion Inhibitors Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Fusion Inhibitors Sales Value, by Application (2019-2030) 4.2.3 Global Fusion Inhibitors Sales Value, by Application (%) (2019-2030) 4.3 Global Fusion Inhibitors Sales Volume by Application 4.3.1 Global Fusion Inhibitors Sales Volume by Application (2019 VS 2023 VS 2030) 4.3.2 Global Fusion Inhibitors Sales Volume, by Application (2019-2030) 4.3.3 Global Fusion Inhibitors Sales Volume, by Application (%) (2019-2030) 4.4 Global Fusion Inhibitors Average Price by Application (2019-2030) 5 Segmentation by Region 5.1 Global Fusion Inhibitors Sales Value by Region 5.1.1 Global Fusion Inhibitors Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Fusion Inhibitors Sales Value by Region (2019-2024) 5.1.3 Global Fusion Inhibitors Sales Value by Region (2025-2030) 5.1.4 Global Fusion Inhibitors Sales Value by Region (%), (2019-2030) 5.2 Global Fusion Inhibitors Sales Volume by Region 5.2.1 Global Fusion Inhibitors Sales Volume by Region: 2019 VS 2023 VS 2030 5.2.2 Global Fusion Inhibitors Sales Volume by Region (2019-2024) 5.2.3 Global Fusion Inhibitors Sales Volume by Region (2025-2030) 5.2.4 Global Fusion Inhibitors Sales Volume by Region (%), (2019-2030) 5.3 Global Fusion Inhibitors Average Price by Region (2019-2030) 5.4 North America 5.4.1 North America Fusion Inhibitors Sales Value, 2019-2030 5.4.2 North America Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 5.5 Europe 5.5.1 Europe Fusion Inhibitors Sales Value, 2019-2030 5.5.2 Europe Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 5.6 Asia Pacific 5.6.1 Asia Pacific Fusion Inhibitors Sales Value, 2019-2030 5.6.2 Asia Pacific Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 5.7 South America 5.7.1 South America Fusion Inhibitors Sales Value, 2019-2030 5.7.2 South America Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 5.8 Middle East & Africa 5.8.1 Middle East & Africa Fusion Inhibitors Sales Value, 2019-2030 5.8.2 Middle East & Africa Fusion Inhibitors Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Fusion Inhibitors Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Fusion Inhibitors Sales Value 6.2.1 Key Countries/Regions Fusion Inhibitors Sales Value, 2019-2030 6.2.2 Key Countries/Regions Fusion Inhibitors Sales Volume, 2019-2030 6.3 United States 6.3.1 United States Fusion Inhibitors Sales Value, 2019-2030 6.3.2 United States Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Fusion Inhibitors Sales Value, 2019-2030 6.4.2 Europe Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Fusion Inhibitors Sales Value, 2019-2030 6.5.2 China Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.5.3 China Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Fusion Inhibitors Sales Value, 2019-2030 6.6.2 Japan Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Fusion Inhibitors Sales Value, 2019-2030 6.7.2 South Korea Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Fusion Inhibitors Sales Value, 2019-2030 6.8.2 Southeast Asia Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Fusion Inhibitors Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Fusion Inhibitors Sales Value, 2019-2030 6.9.2 India Fusion Inhibitors Sales Value by Type (%), 2023 VS 2030 6.9.3 India Fusion Inhibitors Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Bristol-Myers Squibb Company 7.1.1 Bristol-Myers Squibb Company Company Information 7.1.2 Bristol-Myers Squibb Company Introduction and Business Overview 7.1.3 Bristol-Myers Squibb Company Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.1.4 Bristol-Myers Squibb Company Fusion Inhibitors Product Offerings 7.1.5 Bristol-Myers Squibb Company Recent Development 7.2 PeptidePharma 7.2.1 PeptidePharma Company Information 7.2.2 PeptidePharma Introduction and Business Overview 7.2.3 PeptidePharma Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.2.4 PeptidePharma Fusion Inhibitors Product Offerings 7.2.5 PeptidePharma Recent Development 7.3 Incyte 7.3.1 Incyte Company Information 7.3.2 Incyte Introduction and Business Overview 7.3.3 Incyte Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.3.4 Incyte Fusion Inhibitors Product Offerings 7.3.5 Incyte Recent Development 7.4 Astrazeneca 7.4.1 Astrazeneca Company Information 7.4.2 Astrazeneca Introduction and Business Overview 7.4.3 Astrazeneca Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.4.4 Astrazeneca Fusion Inhibitors Product Offerings 7.4.5 Astrazeneca Recent Development 7.5 ViiV Healthcare Limited 7.5.1 ViiV Healthcare Limited Company Information 7.5.2 ViiV Healthcare Limited Introduction and Business Overview 7.5.3 ViiV Healthcare Limited Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.5.4 ViiV Healthcare Limited Fusion Inhibitors Product Offerings 7.5.5 ViiV Healthcare Limited Recent Development 7.6 Frontier Bio Corporation 7.6.1 Frontier Bio Corporation Company Information 7.6.2 Frontier Bio Corporation Introduction and Business Overview 7.6.3 Frontier Bio Corporation Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.6.4 Frontier Bio Corporation Fusion Inhibitors Product Offerings 7.6.5 Frontier Bio Corporation Recent Development 7.7 Trimeris, Inc. 7.7.1 Trimeris, Inc. Company Information 7.7.2 Trimeris, Inc. Introduction and Business Overview 7.7.3 Trimeris, Inc. Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.7.4 Trimeris, Inc. Fusion Inhibitors Product Offerings 7.7.5 Trimeris, Inc. Recent Development 7.8 Progenics Pharmaceuticals 7.8.1 Progenics Pharmaceuticals Company Information 7.8.2 Progenics Pharmaceuticals Introduction and Business Overview 7.8.3 Progenics Pharmaceuticals Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.8.4 Progenics Pharmaceuticals Fusion Inhibitors Product Offerings 7.8.5 Progenics Pharmaceuticals Recent Development 7.9 Schering-Plough (Merck & Co.) 7.9.1 Schering-Plough (Merck & Co.) Company Information 7.9.2 Schering-Plough (Merck & Co.) Introduction and Business Overview 7.9.3 Schering-Plough (Merck & Co.) Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.9.4 Schering-Plough (Merck & Co.) Fusion Inhibitors Product Offerings 7.9.5 Schering-Plough (Merck & Co.) Recent Development 7.10 Biogen 7.10.1 Biogen Company Information 7.10.2 Biogen Introduction and Business Overview 7.10.3 Biogen Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.10.4 Biogen Fusion Inhibitors Product Offerings 7.10.5 Biogen Recent Development 7.11 Vanderbilt University 7.11.1 Vanderbilt University Company Information 7.11.2 Vanderbilt University Introduction and Business Overview 7.11.3 Vanderbilt University Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.11.4 Vanderbilt University Fusion Inhibitors Product Offerings 7.11.5 Vanderbilt University Recent Development 7.12 Genentech 7.12.1 Genentech Company Information 7.12.2 Genentech Introduction and Business Overview 7.12.3 Genentech Fusion Inhibitors Sales, Revenue and Gross Margin (2019-2024) 7.12.4 Genentech Fusion Inhibitors Product Offerings 7.12.5 Genentech Recent Development 8 Industry Chain Analysis 8.1 Fusion Inhibitors Industrial Chain 8.2 Fusion Inhibitors Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Fusion Inhibitors Sales Model 8.5.2 Sales Channel 8.5.3 Fusion Inhibitors Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/15 10:26 157.84 円 166.62 円 202.61 円 |